The efficacy and risks of preoperative embolization of spinal tumors

被引:19
作者
Awad, Al-Wala [1 ]
Almefty, Kaith K. [2 ]
Ducruet, Andrew F. [3 ]
Turner, Jay D. [2 ]
Theodore, Nicholas [2 ]
McDougall, Cameron G. [2 ]
Albuquerque, Felipe C. [2 ]
机构
[1] Univ Arizona, Coll Med, Phoenix, AZ USA
[2] St Josephs Hosp, Barrow Neurol Inst, Div Neurol Surg, Phoenix, AZ USA
[3] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA
关键词
Liquid Embolic Material; Spine; Tumor; Metastatic; INTRAOPERATIVE BLOOD-LOSS; RENAL-CELL CARCINOMA; TRANSARTERIAL EMBOLIZATION; SURGICAL-TREATMENT; EMBOLIC MATERIAL; SINGLE-CENTER; METASTASES; ONYX; EXPERIENCE; CYANOACRYLATE;
D O I
10.1136/neurintsurg-2015-011833
中图分类号
R445 [影像诊断学];
学科分类号
100207 ;
摘要
Background The goal of preoperative embolization of spinal tumors is to improve surgical outcomes by diminishing the vascular supply to the tumor to reduce intraoperative blood loss and operative time. Objective To report our institutional experience with spinal tumor embolization and review the present literature. Methods Clinical records from January 1, 2001 to December 31, 2012 were reviewed and analyzed. Angiograms were used to calculate the percentage reduction in tumor vascularity, and relevant clinical and operative data were collected and analyzed. Results Thirty-seven patients underwent preoperative spinal tumor embolization (24 metastatic and 13 primary lesions) and were included in the study. One complication resulted in transient lower extremity weakness and was attributed to post-embolization swelling, which fully resolved after surgical resection. The transient neurological complication rate was 1/37 (3%) and the permanent rate was 0/37 (0%). The average surgical estimated blood loss (EBL) was 1946mL (100-7000mL) and the average operative time was 330min (range 164-841min). After embolization, tumor blush was reduced by 83% on average. Average pre- and postoperative modified Rankin Scale scores were 2.10 and 1.36, respectively (p=0.03). Cases in which tumor blush was decreased by 90% (classes 1 or 2) after embolization had significantly less operative blood loss than those cases in which <90% (classes 3 or 4) was achieved (mean EBL 1391 vs 2296mL, respectively, p=0.05). Conclusions Spinal tumor embolization is a safe procedure, is associated with few complications, and may improve surgical outcomes by limiting intraoperative blood loss and reducing operative time.
引用
收藏
页码:859 / 864
页数:6
相关论文
共 27 条
[1]  
Berkefeld J, 1999, AM J NEURORADIOL, V20, P757
[2]   Preoperative embolization of spinal tumors [J].
Breslau, J ;
Eskridge, JM .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 1995, 6 (06) :871-875
[3]   PREOPERATIVE SUPERSELECTIVE ARTERIOLAR EMBOLIZATION - A NEW APPROACH TO ENHANCE RESECTABILITY OF SPINAL TUMORS [J].
BROADDUS, WC ;
GRADY, MS ;
DELASHAW, JB ;
FERGUSON, RDG ;
JANE, JA .
NEUROSURGERY, 1990, 27 (05) :755-759
[4]  
BROTHERS MF, 1989, AM J NEURORADIOL, V10, P777
[5]   The surgical treatment of metastatic spinal tumors within the intradural extramedullary compartment [J].
Chow, TSF ;
McCutcheon, IE .
JOURNAL OF NEUROSURGERY, 1996, 85 (02) :225-230
[6]   Preoperative spinal tumor embolization: An institutional experience with Onyx [J].
Ghobrial, George M. ;
Chalouhi, Nohra ;
Harrop, James ;
Dalyai, Richard T. ;
Tjoumakaris, Stavropoula ;
Gonzalez, L. Fernando ;
Hasan, David ;
Rosenwasser, Robert H. ;
Jabbour, Pascal .
CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 (12) :2457-2463
[7]  
Gore P, 2008, NEUROSURGERY, V62, P11
[8]   The utility of Onyx for preoperative embolization of cranial and spinal tumors [J].
Gore, Pankaj ;
Theodore, Nicholas ;
Brasiliense, Leonardo ;
Kim, Louis J. ;
Garrett, Mark ;
Nakaji, Peter ;
Gonzalez, L. Fernando ;
McDougall, Cameron G. ;
Albuquerque, Felipe C. .
NEUROSURGERY, 2008, 62 (06) :1204-1211
[9]   Preoperative transarterial embolization of vertebral metastases [J].
Guzman, R ;
Dubach-Schwizer, S ;
Heini, P ;
Lovblad, KO ;
Kalbermatten, D ;
Schroth, G ;
Remonda, L .
EUROPEAN SPINE JOURNAL, 2005, 14 (03) :263-268
[10]  
Hatrick NC, 2000, RADIOTHER ONCOL, V56, P335